Exact Sciences Co. (NASDAQ:EXAS) Receives $95.40 Average Target Price from Brokerages

Shares of Exact Sciences Co. (NASDAQ:EXASGet Free Report) have been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $95.40.

A number of research analysts have weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. BTIG Research reduced their target price on shares of Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Citigroup dropped their price target on Exact Sciences from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Canaccord Genuity Group reduced their price objective on Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Finally, TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th.

Get Our Latest Stock Report on EXAS

Exact Sciences Price Performance

Shares of EXAS stock opened at $45.25 on Tuesday. The firm has a market capitalization of $8.35 billion, a price-to-earnings ratio of -34.28 and a beta of 1.26. Exact Sciences has a 12-month low of $43.59 and a 12-month high of $100.77. The company has a quick ratio of 1.45, a current ratio of 1.64 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average of $60.95 and a 200-day moving average of $63.39.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). The firm had revenue of $637.52 million during the quarter, compared to analysts’ expectations of $624.95 million. Exact Sciences had a negative return on equity of 7.12% and a negative net margin of 9.48%. On average, equities research analysts forecast that Exact Sciences will post -1.15 earnings per share for the current year.

Insider Activity at Exact Sciences

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $70.00, for a total value of $140,000.00. Following the transaction, the executive vice president now directly owns 71,787 shares in the company, valued at $5,025,090. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the sale, the executive vice president now directly owns 71,787 shares in the company, valued at $5,025,090. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total value of $69,473.25. Following the completion of the transaction, the chief executive officer now directly owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,498 shares of company stock worth $370,105. Company insiders own 1.36% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

Several institutional investors and hedge funds have recently modified their holdings of EXAS. Wolff Wiese Magana LLC grew its position in shares of Exact Sciences by 459.5% during the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after purchasing an additional 340 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its position in Exact Sciences by 65.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock worth $31,000 after buying an additional 179 shares in the last quarter. Able Wealth Management LLC bought a new position in Exact Sciences during the 4th quarter worth $45,000. Valley National Advisers Inc. raised its holdings in Exact Sciences by 29.5% in the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock valued at $53,000 after acquiring an additional 176 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new stake in shares of Exact Sciences during the 1st quarter valued at $55,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Exact Sciences Company Profile

(Get Free Report

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Articles

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.